ID   GAMT_HUMAN              Reviewed;         236 AA.
AC   Q14353; A8K0A0; Q53Y34; Q8WVJ1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Guanidinoacetate N-methyltransferase;
DE            EC=2.1.1.2;
GN   Name=GAMT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8547310; DOI=10.1016/0167-4781(95)00184-0;
RA   Isbrandt D., von Figura K.;
RT   "Cloning and sequence analysis of human guanidinoacetate N-
RT   methyltransferase cDNA.";
RL   Biochim. Biophys. Acta 1264:265-267(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9325156; DOI=10.1006/bbrc.1997.9992;
RA   Jenne D.E., Olsen A.S., Zimmer M.;
RT   "The human guanidinoacetate methyltransferase (GAMT) gene maps to a
RT   syntenic region on 19p13.3, homologous to band C of mouse chromosome
RT   10, but GAMT is not mutated in jittery mice.";
RL   Biochem. Biophys. Res. Commun. 238:723-727(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Isbrandt D., Schmidt A.;
RT   "Gene structure of human guanidinoacetate N-methyltransferase.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   MET-209.
RC   TISSUE=Lymph, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   TISSUE SPECIFICITY, AND INVOLVEMENT IN CCDS2.
RX   PubMed=8651275;
RA   Stoeckler S., Isbrandt D., Hanefeld F., Schmidt B., von Figura K.;
RT   "Guanidinoacetate methyltransferase deficiency: the first inborn error
RT   of creatine metabolism in man.";
RL   Am. J. Hum. Genet. 58:914-922(1996).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE.
RG   Structural genomics consortium (SGC);
RT   "The crystal structure of human guanidinoacetate N-methyltransferase
RT   with SAH.";
RL   Submitted (MAR-2006) to the PDB data bank.
RN   [13]
RP   VARIANT CCDS2 PRO-197.
RX   PubMed=12468279; DOI=10.1016/S1096-7192(02)00175-0;
RA   Battini R., Leuzzi V., Carducci C., Tosetti M., Bianchi M.C.,
RA   Item C.B., Stoeckler-Ipsiroglu S., Cioni G.;
RT   "Creatine depletion in a new case with AGAT deficiency: clinical and
RT   genetic study in a large pedigree.";
RL   Mol. Genet. Metab. 77:326-331(2002).
RN   [14]
RP   VARIANTS CCDS2 SER-20; PRO-51 AND PRO-54.
RX   PubMed=15108290; DOI=10.1002/humu.9238;
RA   Item C.B., Mercimek-Mahmutoglu S., Battini R., Edlinger-Horvat C.,
RA   Stromberger C., Bodamer O., Muehl A., Vilaseca M.A., Korall H.,
RA   Stoeckler-Ipsiroglu S.;
RT   "Characterization of seven novel mutations in seven patients with GAMT
RT   deficiency.";
RL   Hum. Mutat. 23:524-524(2004).
RN   [15]
RP   VARIANTS CCDS2 SER-20 AND TYR-169.
RX   PubMed=15651030; DOI=10.1002/ajmg.a.30226;
RA   Caldeira Araujo H., Smit W., Verhoeven N.M., Salomons G.S., Silva S.,
RA   Vasconcelos R., Tomas H., Tavares de Almeida I., Jakobs C., Duran M.;
RT   "Guanidinoacetate methyltransferase deficiency identified in adults
RT   and a child with mental retardation.";
RL   Am. J. Med. Genet. A 133:122-127(2005).
RN   [16]
RP   VARIANT CCDS2 PRO-197.
RX   PubMed=16293431; DOI=10.1016/j.ymgme.2005.09.017;
RA   Leuzzi V., Carducci C., Carducci C., Matricardi M., Bianchi M.C.,
RA   Di Sabato M.L., Artiola C., Antonozzi I.;
RT   "A mutation on exon 6 of guanidinoacetate methyltransferase (GAMT)
RT   gene supports a different function for isoform a and b of GAMT
RT   enzyme.";
RL   Mol. Genet. Metab. 87:88-90(2006).
RN   [17]
RP   VARIANT CCDS2 PRO-51.
RX   PubMed=16855203; DOI=10.1212/01.wnl.0000234852.43688.bf;
RA   Mercimek-Mahmutoglu S., Stoeckler-Ipsiroglu S., Adami A., Appleton R.,
RA   Araujo H.C., Duran M., Ensenauer R., Fernandez-Alvarez E., Garcia P.,
RA   Grolik C., Item C.B., Leuzzi V., Marquardt I., Muehl A.,
RA   Saelke-Kellermann R.A., Salomons G.S., Schulze A., Surtees R.,
RA   van der Knaap M.S., Vasconcelos R., Verhoeven N.M., Vilarinho L.,
RA   Wilichowski E., Jakobs C.;
RT   "GAMT deficiency: features, treatment, and outcome in an inborn error
RT   of creatine synthesis.";
RL   Neurology 67:480-484(2006).
RN   [18]
RP   VARIANT CCDS2 LEU-50.
RX   PubMed=17101918; DOI=10.1212/01.wnl.0000239153.39710.81;
RA   Lion-Francois L., Cheillan D., Pitelet G., Acquaviva-Bourdain C.,
RA   Bussy G., Cotton F., Guibaud L., Gerard D., Rivier C.,
RA   Vianey-Saban C., Jakobs C., Salomons G.S., des Portes V.;
RT   "High frequency of creatine deficiency syndromes in patients with
RT   unexplained mental retardation.";
RL   Neurology 67:1713-1714(2006).
RN   [19]
RP   VARIANT CCDS2 PRO-166.
RX   PubMed=17466557; DOI=10.1016/j.ymgme.2007.03.006;
RA   Verbruggen K.T., Sijens P.E., Schulze A., Lunsing R.J., Jakobs C.,
RA   Salomons G.S., van Spronsen F.J.;
RT   "Successful treatment of a guanidinoacetate methyltransferase
RT   deficient patient: findings with relevance to treatment strategy and
RT   pathophysiology.";
RL   Mol. Genet. Metab. 91:294-296(2007).
RN   [20]
RP   VARIANT CCDS2 ASN-135.
RX   PubMed=19388150; DOI=10.1111/j.1469-8749.2008.03227.x;
RA   O'Rourke D.J., Ryan S., Salomons G., Jakobs C., Monavari A.,
RA   King M.D.;
RT   "Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of
RT   movement disorder and preserved expressive language.";
RL   Dev. Med. Child. Neurol. 51:404-407(2009).
RN   [21]
RP   VARIANTS CCDS2 ARG-45; GLU-78; ASP-164 AND ARG-169.
RX   PubMed=23660394; DOI=10.1016/j.ymgme.2013.04.006;
RA   Comeaux M.S., Wang J., Wang G., Kleppe S., Zhang V.W., Schmitt E.S.,
RA   Craigen W.J., Renaud D., Sun Q., Wong L.J.;
RT   "Biochemical, molecular, and clinical diagnoses of patients with
RT   cerebral creatine deficiency syndromes.";
RL   Mol. Genet. Metab. 109:260-268(2013).
RN   [22]
RP   VARIANTS CCDS2 CYS-68; VAL-75; PHE-110; TYR-147; PRO-159 AND PRO-208,
RP   VARIANTS THR-8 AND HIS-27, CHARACTERIZATION OF VARIANTS CCDS2 ARG-45;
RP   LEU-50; PRO-51; PRO-54; CYS-68; VAL-75; PHE-110; TYR-147; PRO-159;
RP   PRO-166; TYR-169; PRO-197 AND PRO-208, CHARACTERIZATION OF VARIANTS
RP   THR-8 AND HIS-27, AND FUNCTION.
RX   PubMed=24415674; DOI=10.1002/humu.22511;
RA   Mercimek-Mahmutoglu S., Ndika J., Kanhai W., de Villemeur T.B.,
RA   Cheillan D., Christensen E., Dorison N., Hannig V., Hendriks Y.,
RA   Hofstede F.C., Lion-Francois L., Lund A.M., Mundy H., Pitelet G.,
RA   Raspall-Chaure M., Scott-Schwoerer J.A., Szakszon K.,
RA   Valayannopoulos V., Williams M., Salomons G.S.;
RT   "Thirteen new patients with guanidinoacetate methyltransferase
RT   deficiency and functional characterization of nineteen novel missense
RT   variants in the GAMT gene.";
RL   Hum. Mutat. 35:462-469(2014).
RN   [23]
RP   VARIANTS VAL-71; MET-78; ILE-95; GLN-105; PRO-106; ARG-146; ASP-156;
RP   LEU-157 AND ILE-167, CHARACTERIZATION OF VARIANTS VAL-71; MET-78;
RP   ILE-95; GLN-105; PRO-106; ARG-146; ASP-156; LEU-157 AND ILE-167, AND
RP   FUNCTION.
RX   PubMed=26003046; DOI=10.1007/s00438-015-1067-x;
RA   Desroches C.L., Patel J., Wang P., Minassian B., Marshall C.R.,
RA   Salomons G.S., Mercimek-Mahmutoglu S.;
RT   "Carrier frequency of guanidinoacetate methyltransferase deficiency in
RT   the general population by functional characterization of missense
RT   variants in the GAMT gene.";
RL   Mol. Genet. Genomics 290:2163-2171(2015).
RN   [24]
RP   VARIANTS LEU-44; LEU-76; THR-196; VAL-196 AND THR-224,
RP   CHARACTERIZATION OF VARIANTS LEU-44; LEU-76; THR-196; VAL-196 AND
RP   THR-224, AND FUNCTION.
RX   PubMed=26319512; DOI=10.1016/j.gene.2015.08.045;
RA   Mercimek-Mahmutoglu S., Pop A., Kanhai W., Fernandez Ojeda M.,
RA   Holwerda U., Smith D., Loeber J.G., Schielen P.C., Salomons G.S.;
RT   "A pilot study to estimate incidence of guanidinoacetate
RT   methyltransferase deficiency in newborns by direct sequencing of the
RT   GAMT gene.";
RL   Gene 575:127-131(2016).
CC   -!- FUNCTION: Converts guanidinoacetate to creatine, using S-
CC       adenosylmethionine as the methyl donor (PubMed:26003046,
CC       PubMed:24415674, PubMed:26319512). Important in nervous system
CC       development (PubMed:24415674). {ECO:0000269|PubMed:24415674,
CC       ECO:0000269|PubMed:26003046, ECO:0000269|PubMed:26319512}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + guanidinoacetate =
CC       S-adenosyl-L-homocysteine + creatine. {ECO:0000255|PROSITE-
CC       ProRule:PRU00892}.
CC   -!- PATHWAY: Amine and polyamine biosynthesis; creatine biosynthesis;
CC       creatine from L-arginine and glycine: step 2/2.
CC   -!- SUBUNIT: Monomer. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14353-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14353-2; Sequence=VSP_042722;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in liver.
CC       {ECO:0000269|PubMed:8651275}.
CC   -!- DISEASE: Cerebral creatine deficiency syndrome 2 (CCDS2)
CC       [MIM:612736]: An autosomal recessive disorder characterized by
CC       developmental delay and regression, mental retardation, severe
CC       disturbance of expressive and cognitive speech, intractable
CC       seizures, movement disturbances, severe depletion of creatine and
CC       phosphocreatine in the brain, and accumulation of guanidinoacetic
CC       acid in brain and body fluids. {ECO:0000269|PubMed:12468279,
CC       ECO:0000269|PubMed:15108290, ECO:0000269|PubMed:15651030,
CC       ECO:0000269|PubMed:16293431, ECO:0000269|PubMed:16855203,
CC       ECO:0000269|PubMed:17101918, ECO:0000269|PubMed:17466557,
CC       ECO:0000269|PubMed:19388150, ECO:0000269|PubMed:23660394,
CC       ECO:0000269|PubMed:24415674, ECO:0000269|PubMed:8651275}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. RMT2 methyltransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00892}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z49878; CAA90035.1; -; mRNA.
DR   EMBL; AF010248; AAD04781.1; -; Genomic_DNA.
DR   EMBL; AF010246; AAD04781.1; JOINED; Genomic_DNA.
DR   EMBL; AF010247; AAD04781.1; JOINED; Genomic_DNA.
DR   EMBL; AF188893; AAF01461.1; -; Genomic_DNA.
DR   EMBL; BT007034; AAP35682.1; -; mRNA.
DR   EMBL; AK289465; BAF82154.1; -; mRNA.
DR   EMBL; AC005329; AAC27668.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69505.1; -; Genomic_DNA.
DR   EMBL; BC016760; AAH16760.1; -; mRNA.
DR   EMBL; BC017936; AAH17936.1; -; mRNA.
DR   CCDS; CCDS12064.1; -. [Q14353-1]
DR   CCDS; CCDS45897.1; -. [Q14353-2]
DR   PIR; S62732; S62732.
DR   RefSeq; NP_000147.1; NM_000156.5. [Q14353-1]
DR   RefSeq; NP_620279.1; NM_138924.2. [Q14353-2]
DR   UniGene; Hs.81131; -.
DR   PDB; 3ORH; X-ray; 1.86 A; A/B/C/D=1-236.
DR   PDBsum; 3ORH; -.
DR   ProteinModelPortal; Q14353; -.
DR   SMR; Q14353; -.
DR   BioGrid; 108865; 8.
DR   IntAct; Q14353; 6.
DR   STRING; 9606.ENSP00000403536; -.
DR   DrugBank; DB00148; Creatine.
DR   DrugBank; DB00536; Guanidine.
DR   DrugBank; DB02751; N-[Amino(Imino)Methyl]Glycine.
DR   DrugBank; DB01752; S-Adenosyl-L-Homocysteine.
DR   iPTMnet; Q14353; -.
DR   PhosphoSitePlus; Q14353; -.
DR   BioMuta; GAMT; -.
DR   DMDM; 2498404; -.
DR   OGP; Q14353; -.
DR   EPD; Q14353; -.
DR   PaxDb; Q14353; -.
DR   PeptideAtlas; Q14353; -.
DR   PRIDE; Q14353; -.
DR   DNASU; 2593; -.
DR   Ensembl; ENST00000252288; ENSP00000252288; ENSG00000130005. [Q14353-1]
DR   Ensembl; ENST00000447102; ENSP00000403536; ENSG00000130005. [Q14353-2]
DR   GeneID; 2593; -.
DR   KEGG; hsa:2593; -.
DR   UCSC; uc002lsk.5; human. [Q14353-1]
DR   CTD; 2593; -.
DR   DisGeNET; 2593; -.
DR   GeneCards; GAMT; -.
DR   GeneReviews; GAMT; -.
DR   H-InvDB; HIX0030201; -.
DR   HGNC; HGNC:4136; GAMT.
DR   HPA; HPA051806; -.
DR   MalaCards; GAMT; -.
DR   MIM; 601240; gene.
DR   MIM; 612736; phenotype.
DR   neXtProt; NX_Q14353; -.
DR   OpenTargets; ENSG00000130005; -.
DR   Orphanet; 382; Guanidinoacetate methyltransferase deficiency.
DR   PharmGKB; PA28549; -.
DR   eggNOG; KOG1709; Eukaryota.
DR   eggNOG; ENOG4110T2S; LUCA.
DR   GeneTree; ENSGT00390000018061; -.
DR   HOGENOM; HOG000010290; -.
DR   HOVERGEN; HBG005801; -.
DR   InParanoid; Q14353; -.
DR   KO; K00542; -.
DR   OMA; RYYAFPQ; -.
DR   OrthoDB; EOG091G0EPW; -.
DR   PhylomeDB; Q14353; -.
DR   TreeFam; TF328555; -.
DR   BioCyc; MetaCyc:HS05327-MONOMER; -.
DR   BRENDA; 2.1.1.2; 2681.
DR   Reactome; R-HSA-71288; Creatine metabolism.
DR   UniPathway; UPA00104; UER00580.
DR   EvolutionaryTrace; Q14353; -.
DR   GeneWiki; Guanidinoacetate_N-methyltransferase; -.
DR   GenomeRNAi; 2593; -.
DR   PRO; PR:Q14353; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000130005; -.
DR   CleanEx; HS_GAMT; -.
DR   ExpressionAtlas; Q14353; baseline and differential.
DR   Genevisible; Q14353; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0030731; F:guanidinoacetate N-methyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0008168; F:methyltransferase activity; TAS:Reactome.
DR   GO; GO:0009887; P:animal organ morphogenesis; IEA:Ensembl.
DR   GO; GO:0006601; P:creatine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006600; P:creatine metabolic process; TAS:Reactome.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0046498; P:S-adenosylhomocysteine metabolic process; IBA:GO_Central.
DR   GO; GO:0046500; P:S-adenosylmethionine metabolic process; IBA:GO_Central.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   InterPro; IPR016550; GuanidinoAc_N-MeTrfase.
DR   InterPro; IPR026480; RMT2_dom.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   PIRSF; PIRSF009285; GAMT; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51559; SAM_RMT2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; Methyltransferase; Polymorphism; Reference proteome;
KW   S-adenosyl-L-methionine; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    236       Guanidinoacetate N-methyltransferase.
FT                                /FTId=PRO_0000087430.
FT   DOMAIN       13    236       RMT2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00892}.
FT   REGION       69     74       S-adenosyl-L-methionine binding.
FT   REGION       90     92       S-adenosyl-L-methionine.
FT   REGION      117    118       S-adenosyl-L-methionine binding.
FT   REGION      171    172       Substrate binding.
FT   BINDING      20     20       S-adenosyl-L-methionine.
FT   BINDING      42     42       Substrate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00892}.
FT   BINDING      46     46       Substrate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00892}.
FT   BINDING      50     50       S-adenosyl-L-methionine.
FT   BINDING     135    135       S-adenosyl-L-methionine and substrate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00892}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22223895}.
FT   VAR_SEQ     191    236       ETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITP
FT                                LVTKG -> VRPPEVPHGSPGSDLGWGWEGAAGATLLPGEG
FT                                PFLTPWVGWTVLVHLEIKVLCLAQWLPGAVAQVYNPSTVEG
FT                                RGGQIA (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042722.
FT   VARIANT       8      8       P -> T (rare polymorphism; no effect on
FT                                activity; dbSNP:rs776498025).
FT                                {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071775.
FT   VARIANT      20     20       W -> S (in CCDS2; dbSNP:rs80338734).
FT                                {ECO:0000269|PubMed:15108290,
FT                                ECO:0000269|PubMed:15651030}.
FT                                /FTId=VAR_058102.
FT   VARIANT      27     27       Y -> H (polymorphism; no effect on
FT                                activity; dbSNP:rs200833152).
FT                                {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071776.
FT   VARIANT      44     44       R -> L (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs200339910).
FT                                {ECO:0000269|PubMed:26319512}.
FT                                /FTId=VAR_075290.
FT   VARIANT      45     45       W -> R (in CCDS2; loss of activity).
FT                                {ECO:0000269|PubMed:23660394,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071777.
FT   VARIANT      50     50       M -> L (in CCDS2; retains no significant
FT                                activity; dbSNP:rs104894694).
FT                                {ECO:0000269|PubMed:17101918,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_058103.
FT   VARIANT      51     51       H -> P (in CCDS2; retains no significant
FT                                activity). {ECO:0000269|PubMed:15108290,
FT                                ECO:0000269|PubMed:16855203,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_058104.
FT   VARIANT      54     54       A -> P (in CCDS2; loss of activity).
FT                                {ECO:0000269|PubMed:15108290,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_058105.
FT   VARIANT      68     68       G -> C (in CCDS2; retains no significant
FT                                activity). {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071778.
FT   VARIANT      71     71       M -> V (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs372027428).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075291.
FT   VARIANT      75     75       A -> V (in CCDS2; retains no significant
FT                                activity). {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071779.
FT   VARIANT      76     76       S -> L (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs150338273).
FT                                {ECO:0000269|PubMed:26319512}.
FT                                /FTId=VAR_075292.
FT   VARIANT      78     78       V -> E (in CCDS2).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071780.
FT   VARIANT      78     78       V -> M (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs141358977).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075293.
FT   VARIANT      95     95       V -> I (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs140778208).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075294.
FT   VARIANT     105    105       R -> Q (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs148838075).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075295.
FT   VARIANT     106    106       Q -> P (disrupts enzymatic activity;
FT                                dbSNP:rs145817990).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075296.
FT   VARIANT     110    110       V -> F (in CCDS2; retains no significant
FT                                activity; dbSNP:rs753198836).
FT                                {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071781.
FT   VARIANT     135    135       D -> N (in CCDS2; dbSNP:rs774144200).
FT                                {ECO:0000269|PubMed:19388150}.
FT                                /FTId=VAR_071782.
FT   VARIANT     146    146       T -> R (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs149821870).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075297.
FT   VARIANT     147    147       H -> Y (in CCDS2; retains no significant
FT                                activity). {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071783.
FT   VARIANT     156    156       A -> D (disrupts enzymatic activity;
FT                                dbSNP:rs368221789).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075298.
FT   VARIANT     157    157       F -> L (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs372260609).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075299.
FT   VARIANT     159    159       L -> P (in CCDS2; loss of activity).
FT                                {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071784.
FT   VARIANT     164    164       G -> D (in CCDS2; dbSNP:rs760101382).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071785.
FT   VARIANT     166    166       L -> P (in CCDS2; loss of activity).
FT                                {ECO:0000269|PubMed:17466557,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071786.
FT   VARIANT     167    167       T -> I (disrupts enzymatic activity;
FT                                dbSNP:rs374762419).
FT                                {ECO:0000269|PubMed:26003046}.
FT                                /FTId=VAR_075300.
FT   VARIANT     169    169       C -> R (in CCDS2).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071787.
FT   VARIANT     169    169       C -> Y (in CCDS2; retains no significant
FT                                activity; dbSNP:rs121909272).
FT                                {ECO:0000269|PubMed:15651030,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_058106.
FT   VARIANT     196    196       A -> T (polymorphism; no effect on
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:26319512}.
FT                                /FTId=VAR_075301.
FT   VARIANT     196    196       A -> V (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs565109128).
FT                                {ECO:0000269|PubMed:26319512}.
FT                                /FTId=VAR_075302.
FT   VARIANT     197    197       L -> P (in CCDS2; loss of activity).
FT                                {ECO:0000269|PubMed:12468279,
FT                                ECO:0000269|PubMed:16293431,
FT                                ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_058107.
FT   VARIANT     208    208       R -> P (in CCDS2; retains no significant
FT                                activity; dbSNP:rs767887772).
FT                                {ECO:0000269|PubMed:24415674}.
FT                                /FTId=VAR_071788.
FT   VARIANT     209    209       T -> M (in dbSNP:rs17851582).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_025723.
FT   VARIANT     224    224       A -> T (polymorphism; no effect on
FT                                enzymatic activity; dbSNP:rs141471799).
FT                                {ECO:0000269|PubMed:26319512}.
FT                                /FTId=VAR_075303.
FT   HELIX        17     20       {ECO:0000244|PDB:3ORH}.
FT   STRAND       25     27       {ECO:0000244|PDB:3ORH}.
FT   STRAND       31     36       {ECO:0000244|PDB:3ORH}.
FT   STRAND       39     43       {ECO:0000244|PDB:3ORH}.
FT   HELIX        44     46       {ECO:0000244|PDB:3ORH}.
FT   HELIX        47     57       {ECO:0000244|PDB:3ORH}.
FT   TURN         58     60       {ECO:0000244|PDB:3ORH}.
FT   STRAND       62     67       {ECO:0000244|PDB:3ORH}.
FT   HELIX        73     78       {ECO:0000244|PDB:3ORH}.
FT   STRAND       83     90       {ECO:0000244|PDB:3ORH}.
FT   HELIX        93    102       {ECO:0000244|PDB:3ORH}.
FT   HELIX       103    105       {ECO:0000244|PDB:3ORH}.
FT   STRAND      107    115       {ECO:0000244|PDB:3ORH}.
FT   HELIX       117    120       {ECO:0000244|PDB:3ORH}.
FT   HELIX       121    123       {ECO:0000244|PDB:3ORH}.
FT   STRAND      129    134       {ECO:0000244|PDB:3ORH}.
FT   HELIX       141    143       {ECO:0000244|PDB:3ORH}.
FT   TURN        144    146       {ECO:0000244|PDB:3ORH}.
FT   HELIX       147    154       {ECO:0000244|PDB:3ORH}.
FT   HELIX       156    159       {ECO:0000244|PDB:3ORH}.
FT   STRAND      160    168       {ECO:0000244|PDB:3ORH}.
FT   HELIX       171    177       {ECO:0000244|PDB:3ORH}.
FT   TURN        178    181       {ECO:0000244|PDB:3ORH}.
FT   HELIX       185    192       {ECO:0000244|PDB:3ORH}.
FT   HELIX       194    200       {ECO:0000244|PDB:3ORH}.
FT   HELIX       204    206       {ECO:0000244|PDB:3ORH}.
FT   STRAND      207    213       {ECO:0000244|PDB:3ORH}.
FT   STRAND      226    234       {ECO:0000244|PDB:3ORH}.
SQ   SEQUENCE   236 AA;  26318 MW;  6B8E845CE56189F5 CRC64;
     MSAPSATPIF APGENCSPAW GAAPAAYDAA DTHLRILGKP VMERWETPYM HALAAAASSK
     GGRVLEVGFG MAIAASKVQE APIDEHWIIE CNDGVFQRLR DWAPRQTHKV IPLKGLWEDV
     APTLPDGHFD GILYDTYPLS EETWHTHQFN FIKNHAFRLL KPGGVLTYCN LTSWGELMKS
     KYSDITIMFE ETQVPALLEA GFRRENIRTE VMALVPPADC RYYAFPQMIT PLVTKG
//
